NasdaqGS:DNLIBiotechs
Denali Therapeutics (DNLI) Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed?
Denali Therapeutics Inc. recently reported fourth-quarter and full-year 2025 results, with net losses of US$128.55 million for the quarter and US$512.54 million for the year, and also filed a US$200.73 million shelf registration for 9,370,929 common shares tied to an ESOP-related offering.
Alongside these wider losses and potential equity issuance, Denali is maintaining visibility with investors through a company presentation at TD Cowen’s 46th Annual Health Care Conference held on March 4,...